Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli

International Journal of Antimicrobial Agents
G E SteinDavid P Nicolau

Abstract

Increasing resistance to fluoroquinolones in uropathogens has become a clinical concern. The purpose of this study was to analyse the urinary bactericidal activity (UBA) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. Ten healthy adult subjects (aged 23-60 years) received single doses of levofloxacin (250, 500, 750 and 1000 mg) and then blood and urine samples were collected in intervals (0-1.5, 1.5-4, 4-8, 8-12 and 12-24h) over 24h. Both serum and urine concentrations were measured by a validated high-performance liquid chromatography assay. Bactericidal titres in urine were determined against E. coli isolates with minimum inhibitory concentrations of 0.125, 4, 8, 16, 32 and 64microg/mL for levofloxacin. The mean serum pharmacokinetic parameters for these doses of levofloxacin were similar to previously published values. The mean peak urinary concentrations (0-1.5h) were 210, 347, 620 and 536microg/mL for the 250, 500, 750 and 1000 mg dose, respectively. Each dose of levofloxacin exhibited early (0-1.5h time period) bactericidal activity in urine in virtually all subjects against E. coli strains with MICs<or=32microg/mL. Moreover, high-dose (750 mg and 1000 mg) levofloxacin provided prolonged (8-...Continue Reading

References

Jul 24, 2002·International Journal of Antimicrobial Agents·Kalpana Gupta, Walter E Stamm
Jul 5, 2003·Science·Gregory G AndersonScott J Hultgren
Oct 7, 2003·International Journal of Antimicrobial Agents·Thomas M Hooton
Jun 19, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas M HootonLindsay E Nicolle
Aug 4, 2004·International Journal of Antimicrobial Agents·Gary E Stein, Sharon Schooley
Mar 5, 2005·The American Journal of Medicine·Jeffrey A LinderRandall S Stafford
Feb 13, 2007·International Journal of Antimicrobial Agents·Loren G MillerAngela W Tang
Aug 31, 2007·International Journal of Antimicrobial Agents·Florian M E WagenlehnerKurt G Naber
Dec 25, 2007·International Journal of Antimicrobial Agents·Lindsay NicolleGeorge Zhanel

❮ Previous
Next ❯

Citations

Nov 5, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Y-H ChenP-R Hsueh
Mar 29, 2011·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Po-Ren HsuehYao-Shen Chen
Apr 26, 2013·Expert Opinion on Pharmacotherapy·Cédric RafatAlexandre Hertig
Sep 7, 2016·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Yun LiYuan Lyu
May 12, 2010·Expert Review of Anti-infective Therapy·Ayman M Noreddin, Walid F Elkhatib
May 24, 2017·The Journal of Antimicrobial Chemotherapy·Thomas MaitreNicolas Veziris
Nov 19, 2010·Postgraduate Medicine·Mazen S BaderAnnie Brooks
May 3, 2019·Journal of Clinical Microbiology·Tam T VanSusan M Butler-Wu
Jun 23, 2018·Microbiology Spectrum·Luca GuardabassiScott Weese

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.